These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 37149155)

  • 21. Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
    Hach T; Shakeri-Nejad K; Bigaud M; Dahlke F; de Micco M; Petricoul O; Graham G; Piani-Meier D; Turrini R; Brinkmann V; Nicoletti F
    J Interferon Cytokine Res; 2023 Jun; 43(6):246-256. PubMed ID: 36454249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.
    Chun J; Kihara Y; Jonnalagadda D; Blaho VA
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():149-170. PubMed ID: 30625282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
    Coyle PK; Freedman MS; Cohen BA; Cree BAC; Markowitz CE
    Ann Clin Transl Neurol; 2024 Apr; 11(4):842-855. PubMed ID: 38366285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
    Stamatellos VP; Papazisis G
    Curr Rev Clin Exp Pharmacol; 2023; 18(1):39-50. PubMed ID: 35418296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
    Constantinescu V; Akgün K; Ziemssen T
    Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):675-693. PubMed ID: 36260948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases.
    Kar SS; Gharai SR; Sahu SK; Ravichandiran V; Swain SP
    Curr Top Med Chem; 2024; 24(28):2431-2446. PubMed ID: 38676503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
    Yang S; Li X; Wang J; Wang T; Xu Z; Gao H; Chen G
    Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral Therapies for Multiple Sclerosis.
    Faissner S; Gold R
    Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation.
    Roggeri A; Schepers M; Tiane A; Rombaut B; van Veggel L; Hellings N; Prickaerts J; Pittaluga A; Vanmierlo T
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ponesimod for the treatment of relapsing multiple sclerosis.
    Baldin E; Lugaresi A
    Expert Opin Pharmacother; 2020 Nov; 21(16):1955-1964. PubMed ID: 32808832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.
    Correale J; Halfon MJ; Jack D; Rubstein A; Villa A
    Mult Scler Relat Disord; 2021 Nov; 56():103264. PubMed ID: 34547609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.
    Bordet R; Camu W; De Seze J; Laplaud DA; Ouallet JC; Thouvenot E
    Rev Neurol (Paris); 2020; 176(1-2):100-112. PubMed ID: 31757428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.
    Schoedel KA; Kolly C; Gardin A; Neelakantham S; Shakeri-Nejad K
    Psychopharmacology (Berl); 2022 Jan; 239(1):1-13. PubMed ID: 34773483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
    Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J
    FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
    Chaudhry BZ; Cohen JA; Conway DS
    Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis.
    Satyanarayan S; Safi N; Sorets T; Filomena S; Zhang Y; Klineova S; Fabian M; Horng S; Tankou S; Miller A; Krieger S; Lublin F; Sumowski J; Katz Sand I
    Mult Scler Relat Disord; 2022 Jun; 62():103737. PubMed ID: 35533419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
    Zhao Z; Lv Y; Gu ZC; Ma CL; Zhong MK
    Front Immunol; 2021; 12():795574. PubMed ID: 34950154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis.
    Bascuñana P; Möhle L; Brackhan M; Pahnke J
    Drugs R D; 2020 Sep; 20(3):197-207. PubMed ID: 32696271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.